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Abstract: Carnitine can be considered a conditionally essential nutrient for its importance in human
physiology. This paper provides an updated picture of the main features of carnitine outlining
its interest and possible use. Particular attention has been addressed to its beneficial properties,
exploiting carnitine’s properties and possible use by considering the main in vitro, in animal, and
human studies. Moreover, the main aspects of carnitine-based dietary supplements have been
indicated and defined with reference to their possible beneficial health properties.
Keywords: carnitine; food supplements; nutraceuticals; in vitro studies; in animal studies;
in humans studies
1. Carnitine: An Overview of Its Main Features
Carnitine (n3-hydroxy-4-N,N,N-trimethylaminobutyrate; 3-hydroxy-4-(trimethylazaniumyl)
butanoate (IUPAC name); β-hydroxy-γ-N-trimethylaminobutyric acid) is an amino acid derivative
that exists as one of the d/l stereoisomers, l-carnitine being the biologically active isomer form of
carnitine, naturally occurring in animals, while the d-carnitine is also active, but inhibits the effect
of l-carnitine and is toxic. It is a naturally occurring endogenous metabolite which can be found
in most mammals, it is a water-soluble molecule, and it has been reported to have many biological
functions. Carnitine can be considered as a conditionally essential nutrient for its importance in
human physiology [1]. The molecular structure of carnitine (C7H15NO3, MW = 161.2 g/mol, solubility
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>2500 g/L at a temperature of 20 ◦C; PubChem CID: 288) is shown in Figure 1. At a pH value of 3.8,
it is a zwitterion, due to positively charged quaternary ammonium groups and carboxylate, and it
dissolves easily in water at a temperature of 20 ◦C.
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The biological functions of carnitine are summarized in Figure 3. Many health-beneficial
actions of carnitine have been identified and reported, including suppression of apoptosis, correction
of cytotoxicity by excessive acyl groups, and stabilization of the erythrocyte membrane [15] and
anti-inflammatory and antioxidant properties [16]. It has also been reported that carnitine can improve
insulin resistance [17], and it is useful in cardiovascular diseases [18,19] and cancer [20].
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Moreover, it has been found by Hathcock et al. that carnitine can be considered a safe nutrient [21],
with adverse outcomes typically limited to mild gastrointestinal discomfort when individuals ingest
high dosages (>5 g/day). l-carnitine at a concentration of 2000 mg/day is considered to be unlikely
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to provoke unwanted side effects and is safe for human beings [21]. The administration of carnitine
supplements has been documented for its safety and efficiency and reported in many studies [14,21].
2. An Updated Shot of Beneficial Properties: In Vitro and In Vivo Studies
Many in vitro studies [22–29], and in vivo studies of animals [30–47] and humans [48–59] have
reported different beneficial functions for carnitine. In the following, the main activities observed
are reported.
2.1. In Vitro Activity
Relevant in vitro studies on l-carnitine are reported in Table 1.
Table 1. An up-to-date picture of in vitro studies of l-carnitine.
Condition Activity Effect References
In vitro Anticancer effects Reduced the levels of methylmalonicacidemia and Propionicacidemia in peripheral leukocytes. [22]
In vitro Antioxidant effects l-carnitine could elevate in vitro human sperm motility. [23]
In vitro Antioxidant effects Inhibited acrylamide-induced genotoxicity in human lymphocytesthrough the improvement of oxidative stress. [24]
In vitro Antioxidant effects Inhibited ROS production and reduced antioxidant activity. [25]
In vitro Anti-aging effect Decreased epigenetic modification of hTERT gene promoter and thenumbers of senescent cells, and increased activity of telomerase. [26]
In vitro Hepatoprotective effect Inhibited the inflammatory mediator iNOS through the suppressionof NF-kB activity in IL-1β-stimulated hepatocytes. [27]
In vitro Anti-angiogenic effect
Suppressed the activation of ICAM-1 and NF-kB and
down-regulated the activation of FAK, CXCR4, CXCL12, VEGFR2
and VEGF pathways.
[28]
In vitro Neuroprotective effect Inhibited methamphetamine-induced activation of MMP-9 [29]
Carnitine showed in vitro anticancer activity by preventing colon cancer cell (Caco-2 cells) proliferation
via a reduction in prostaglandin E2 synthesis and induction of colon cancer cell apoptosis [60]. In several
prostate cancer cell lines, acetyl-l-carnitine acted as an anti-prostate cancer agent by inhibiting the
production of chemokines CXCL12 and CCL2 as well as CXCR4 (chemokine ligand-receptor) and
pro-inflammatory cytokines (IFN-γ and TNF-α) [61]. Huang et al. evaluated the in vitro anticancer role
of carnitine in samples of HepG2 tumor-bearing mice, primary cultured thymocytes, human SMMC-7721,
and hepatoma HepG2 cell lines. The main findings, following l-carnitine treatment, were prevention of
cancer cell growth; inhibition of Histone Deacetylases HDAC I/II activities caused by l-carnitine binding
to HDAC active sites; elevation of histone acetylation and acetylated lysine accumulation; and induction
of p21cip1 gene, mRNA and protein expression in cancer cells [62].
Pre-treatment with acetyl-l-carnitine and l-carnitine exhibited neuroprotective activity for prevention
of hypoxia-ischemia injury, via an increase in the activity levels of ATPase and superoxide dismutase
(SOD) as well as a decrease in the level of malondialdehyde (MDA), oxygen-glucose deprivation
(OGD)-induced cell death, injury and apoptosis [63]. The in vitro l-carnitine has been reported to reduce
phenylalanine-induced DNA damage [64]. The administration of acetyl-l-carnitine (500 µM) exhibited a
neuroprotective role by restoring synaptic plasticity and transmission [65]. In a study by Bavari et al. [66],
the neuroprotective effect of l-carnitine (5 mM) controlled, within 18 h, caffeine cytotoxicity through
the regulation of apoptosis-related caspase-3 activity, reducing the DNA fragmentation, inhibition of
reactive oxygen species (ROS) generation, elevation of endogenous anti-oxidant defense systems, and the
prevention of lipid oxidation. In vitro accumulated l-carnitine has been used to control DNA damage
and oxidative damage in patients with mitochondrial fatty acid oxidation disorders [67].
l-carnitine has been also shown to manage fructose-induced hepatic steatosis in HepG2 cells, due
to activation of antioxidant system, maintenance of mitochondrial homeostasis, and regulation of Nrf2
(nuclear factor erythroid 2–related factor 2) and SOD activity [68]. l-carnitine can increase antioxidant
and mitochondrial functions in human osteoblast-like cells, via up-regulation of osteopontin, bone
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sialoprotein, transcription factor Sp7(Osterix), and RUNX2 genes; phosphorylation of AKT and
ERK1/2; and enhanced phosphorylation of Ca2+/calmodulin-dependent protein kinase II [69]. In vitro
post-oxidative stress glaucoma was controlled by carnitine through reducing pathologic optic-disk
excavation, typical cell stress markers such as caspase 3 and ubiquitin, inducible nitric oxide synthase,
and glial fibrillary acidic protein expression [70]. In a recent study, the lifespan of human mesenchymal
stem cells obtained from aged participants was prolonged, by lengthening telomere and increasing
the expression of the hTERT gene, following the use of l-carnitine (0.2 mM) for two days [71]. In an
in vitro study, performed in blood leukocytes, by Rodrigues et al. [72], administration of L-carnitine
(30 and 150 µM) prevented DNA damage induced by l-2-hydroxyglutaric and d-2-hydroxyglutaric in
l-2-hydroxyglutaric-aciduria-affected patients. The effects of l-carnitine on different parameters of
oxidative stress induced by menadione have been evaluated in myoblastic C2C12 cells: the results
indicated a reduction in autophagy and ROS production [73]. In another recent study, human sperm
morphology and sperm count were improved by 40 µg l-carnitine + coenzyme Q10 (CoQ10) treatment,
while DNA fragmentation was reduced [74].
2.2. In-Animal Studies
Table 2 presents an updated picture of studies based on l-carnitine which have been conducted
in animals.
Table 2. An updated picture of studies based on l-carnitine conducted inanimal models.
Condition Activity Effect References
In-animal model Antioxidant effects Symptom improvement observed by inducing potential functionof the CNS and short-term plasticity. [30]
In-animal model Antioxidant effects
Impeded age-related mitochondrial dysfunction by reducing
oxidative stress, age-related alterations of mitochondrial dynamics
and biogenesis, and activation of PGC-1α/β coactivators.
[31]
In-animal model Anti-diabetic effects An improvement of glucose metabolism in mice with insulinresistant [32]
In-animal model Anti-diabetic effects Reduction in the serum levels of adiponectin. [33]
In-animal model Anti-inflammatory andanti-oxidant effects
Managed histological and inflammation damage, apoptosis,
mitochondrial dysfunction and arsenic-induced hepatotoxicity. [34]
In-animal model Antioxidant effect Upregulation of nrf2 expression and elevation of GSH and TAClevels. [35]
In-animal model Cardioprotective effect Controlled the cardiac toxicity induced by 75- and 150-mg/Kg BWaspartme. [36]
In-animal model Anti-obesity effect Reduction in elevated plasma lipids in obese Zucker rats. [37]
In-animal model
Immunostimulatory
and radioprotective
role
Reduced sperm abnormalities, modified severe tubular
degeneration and increased serum testosterone levels. [38]
In-animal model Enhanced exerciseendurance
Reduced body fat, increased maximum running time, and
elevated mitochondrial biogenesis, oxidative metabolism and
fatty acid adsorption.
[39]
In-animal model Cardioprotective effect Inhibited 6-Gy γ-radiation-induced toxicity. [40]
In-animal model Antioxidant effect Prevented NaAsO2-induced oxidative damage in rat. [41]
In-animal model Treatment of muscleatrophy
Prevented muscle atrophy by inhibiting the ubiquitin proteasome
pathway. [42]
In-animal model Anti-atherosclerosiseffect Prevented the production of trimethylamine N-oxide. [43]
In-animal model Antioxidant effect Decreased the oxidative stress at least in the heart ofoophorectomized rats. [44]
In-animal model Antioxidant effect Decreased acrylamide-toxicity in spleen and thymus tissues inmice. [45]
In-animal model Antioxidant effect l-carnitine (200 mg/kg BW) for 11 weeks prevented dimethoatetoxicity in rats. [46]
In-animal model Antioxidant effect
Reduction in PCC (protein oxidation marker), TBARS (lipid
peroxidation marker), caspase-3, DNA fragmentation,
cyclobutane pyrimidine dimers, 8-oxo-2′-deoxyguanosine
(8-oxo-dG) as well as proinflammatory cytokines IL-1β, IL-6, and
TNF-α downregulation, upregulation of PCNA (DNA repair
proliferating cell nuclear antigen) protein, removed c-Fos and
oxidative stress-sensitive signaling protein p38.
[47]
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Taking the anti-histamine drugs cetirizine hydrochloride and chlorpheniramine maleate combined
with l-carnitine showed a hepatoprotective effect in animal models, via a reduction in oxidative
stress and an improvement in liver function due to the elevation of serum albumin levels and a
reduction in serum alkaline phosphatase (ALP), aspartate transferase (AST), and alanine transferase
(ALT) levels; this treatment also enhanced hepatic glutathione (GSH) levels and reduced hepatic MDA
compared with a control [75]. Ahmed et al. used 50 mg/kg/day of atorvastatin in rats for induction of
hepatoxicity, and then utilized 300 mg/kg/day of oral l-carnitine and 500 IU/kg/day of oral vitamin
D3. Their results showed a decrease in serum levels of creatine kinase, aspartate aminotransferase,
and alanine aminotransferase. Furthermore, histological examinations revealed protection of muscle
and liver tissues against the toxic effects of atorvastatin [76]. The use of nicotinamide riboside plus
l-carnitine in high-fat-diet-treated mice with non-alcoholic fatty liver disease induced anti-obesogenic
hepatoprotective activity due to regulation of INSR, PPARGC1B, SREBF, SCAP, and ACOX, as well as
reduction of hepatic steatosis, fat mass, and obesity [77]. Administration of 200 mg/kg/day of coenzyme
Q10 plus 50 mg/kg/day of l-carnitine in CCl4 hepatoxicity-induced rats exhibited the prophylactic effect
observed [78]. In a recent study, l-carnitine showed a free radical scavenger effect in ethanol-intoxicated
rats through the inhibition of hepatocyte function modification [79]. Induction of renal and pancreatic
injuries by cyclosporine (15 mg/kg/day) in rats was treated by l-carnitine (50 or 200 mg/kg/day) for a
month, the result of which was inhibition of LC3-II and caspase-3 expression, suppression of 8-OHdG
and TGF-β1 expression, improved inflammation and renal function, decreased HbA1c and plasma
glucose levels, and elevated plasma insulin level [80]. In another study, the use of l-carnitine prevented
non-alcoholic steatohepatitis in mice by blocking inflammatory cytokines, preventing hepatic oxidative
stress markers and elevating hepatic gene expression [81].
The administration of acetyl-l-carnitine prevented atherosclerosis onset in Wistar rats by
blocking the expression of oxidative-stress-related genes, controlling inflammation parameters, and
regulating blood lipids, as well as displaying myocardial protection and acting against atherosclerotic
cardiovascular disease, by reducing mRNA levels, iNOS, IL-1b, TNF-a and CPR protein in the hearts
and aortas of rats with induced atherosclerosis [82]. Blanca et al. found that sunitinib produced
cardiac toxicity via the involvement of fibrotic and inflammation processes mediated by transcription
factor NF-kB, and they also reported that l-carnitine showed a protective effect against secondary
fibrotic process, cardiac inflammation, and arterial hypertension induced with sunitinib in Wistar
rats [83]. Co-administration of 300 mg/kg of l-carnitine plus 10 mg/kg of olmesartan could control
doxorubicin-induced (20 mg/kg) cardiotoxicity in rats, through elevation of cardiac levels of glutathione
and superoxide dismutase and reduction of cardiac levels of malondialdehyde, transforming growth
factor Beta, NF-kB, myeloperoxidase, Interleukin IL-1β, intercellular adhesion molecules-1, tumor
necrosis factor-alpha and caspase-3 [84]. The supplementation of propionyl-l-carnitine in a hamster
cheek pouch with ischemia–reperfusion injury prevented microvascular modifications through a
reduction in E-selectin expression, resulting in permeability enhancement and poor leukocyte
adhesion [85]. In one study, l-carnitine showed an antihypertensive function in rats with heart
failure with preserved ejection fractions through an increasing the prostacyclin synthesis and the
expression of fatty acid desaturase, respectively [86]. The use of l-carnitine (400 mg/kg/day) had a
health-promoting effect on hypertension-associated cardiac fibrosis in rats through the down-regulation
of CTGF, TGF-β1 and NOX2/4, and a reduction in cardiac fibrosis [87].
The use of l-carnitine plus selenium for a month to treat cadmium-induced damage in male
mice during could reduce DNA damage and histopathological abnormalities and increase the activity
of antioxidant enzymes [88]. The treatment of rats with l-carnitine (50 mg/kg/day) for 7 months
exhibited antioxidant properties by regulating Bax and Bcl-2, dropping caspase-3 activity, elevating total
antioxidant activity, and scavenging oxygen free radicals [89]. Others reported that the administration
of L-carnitine (500 mg/kg) showed antioxidant and protective effects on testicular ischemia-reperfusion
damage in rats [90]. In a study by Boyacioglu et al., the use of L-carnitine in rats controlled
contrast-induced nephropathy through a preventative function [91].
Molecules 2020, 25, 2127 7 of 19
In a recent study, adult male rats received busulfan plus l-carnitine/arginine, and, as a result,
showed reduced busulfan cytotoxicity, conserved cell energy, reduced oxidative stress, and better
semen parameters [92]. Masoumi-Ardakani et al. [93] administered 300 mg/kg/day of l-carnitine to
48 male rats with Streptozotocin-induced diabetes for 35 days and observed an increase in pancreatic
and serum levels of glutathione peroxidase, superoxide dismutase, and total antioxidant status.
Others reported that bone microstructural features were improved and bone resorption was slowed
following the administration of l-carnitine in aging ovariectomized rats, due to the reduction in bone
turnover [94]. Evaluating the effect of hyperbaric oxygen on lipid metabolism dysfunction in high fat
diet-fed mice showed an increase in the expression of PPARα, skeletal muscle and circulation levels
of l-carnitine [95]. In one study, 300 mg/kg/day of acetyl-l-carnitine for 28 days in rats attenuated
OP-induced haemotoxicity [96].
2.3. In Human Studies
An up-to-date picture of studies conducted in humans is presented in Table 3.
Table 3. An up-to-date picture of in vivo studies of l-carnitine.
Condition Activity Administration Effect References
Clinical trial Cardioprotectiveeffect
Daily oral l-carnitine (50 mg/kg)
in patients with ischemic heart
failure for 10 days
Enhancement of cardiac efficiency,
restoration of cardiac energy
metabolism, and elimination of toxic
mitochondrial products.
[48]
Clinical trial Cardioprotectiveeffect
l-carnitine supplementation at
the concentration of 2 g/day for
8 weeks in patients with
Pemphigus vulgaris
Reduced serum levels of cystatin C,
BMP4 and OPN as well as increased
serum levels of carnitine.
[49]
Clinical trial Anti-inflammatoryeffects
Administration of carnitine (250
mg/day) in females with
polycystic ovary syndrome for
12 weeks
Decreased carotid intima-media
thickness (CIMT) and plasma nitric
oxide.
[50]
Clinical trial Antioxidanteffect
l-carnitine supplementation at
the concentrations of 10 mM
and 30 mM for 55 days
Elevated sulfhydryls and ascorbic
acid uptake, preserved glutathione
level, enhanced sulfhydryls and
ascorbic acid levels, preserved lipid
peroxidation, haemolysis and
haemoglobin, and modulated
antioxidants.
[51]
Clinical trial Antioxidanteffects
Administration of l-carnitine
(100 mg/kg day) in patients with
glutaric acidemia type I for 2
month
Prevented oxidative damage and
increased the removal of toxic
metabolites in patients with type I
glutaric aciduria.
[53]
Clinical trial
Embryonic
development
effect
Administration of l-carnitine
(1000 mg/day) for 82 days
An improvement of oocyte
developmental competence in
patients with in-vitro
fertilization-embryo transfer.
[55]
Clinical trial Anti-anemiaeffect
The administration of
l-carnitine (20 mg/kg/day) for
three months in dialysis children
A restoration and normalized
circulation of plasma free carnitine
(FC) levels
[56]
Clinical trial Anti-autismeffect
Administration of l-carnitine
(50 mg/kg/day bodyweight) for
three months
An improvement of autism symptoms
based on autism treatment evaluation
checklist (ATEC) scores, modified
clinical global impression (CGI), and
childhood autism rating scale (CARS)
[57]
Clinical trial Anti-autismeffect
Administration of l-carnitine
(100 mg/kg/day body weight) in
children
An enhancement of total and free
carnitine levels, a reduction of autism
severity and an improvement of
autistic behavior
[58]
Clinical trial Anti-autismeffect
Administration of l-carnitine
(200 mg/kg/day) in male subjects
aged 5 years for 4.5 months
A gradual improvement of autism
symptoms [59]
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The findings of a recent systematic review and meta-analysis of randomized clinical trials regarding
l-carnitine supplementation showed an amelioration of muscle soreness and an improvement in muscle
damage biomarkers, due to a decrease in lactate dehydrogenase, myoglobin and creatine kinase [97].
In a study by Chae et al. [98], daily administration of two or three 500-mg/ l-carnitine tablets reduced
imatinib-induced muscle cramps in gastrointestinal stromal tumor (GIST) patients. A 750 mg/day dose
of l-carnitine for 8 weeks in female patients with knee osteoarthritis reduced the pain intensity and
serum inflammatory mediators such as matrix metalloproteinases-1 and Interleukine-1b [99]. In a
recent study, supplementation of l-carnitine (750 mg/day) for 8 weeks in patients with osteoarthritis
caused knee pain improvement and reduced serum inflammatory markers (namely MMP-1, and
IL-1β) [99].
Kazemian et al. [100] reported a neuroprotective function in 100 patients with ischemic
cerebrovascular injury, following the use of fat emulsion and l-carnitine, which decreased S100B
biomarker levels. Reportedly, patients with painful peripheral neuropathy have been treated by the
administration of acetyl-l-carnitine [101].
Abolfathi et al. [102] conducted a clinical trial to evaluate the effect of carnitine in patients
with nonalcoholic fatty liver disorder and found a decrease in homeostasis model assessment of
insulin resistance, triglycerides, alanine aminotransferase, and aspartate aminotransferase. In a
systematic review and meta-analysis by Thiagarajan et al. [103], the effect of dietary l-carnitine
supplementation was reviewed quantitatively and qualitatively in randomized trials (sample size
of 338 individuals) from Iran, South Korea, and Italy. Decreases in Homeostatic Model Assessment
for Insulin Resistance (HOMA-IR), liver fat, and serum alanine aminotransferase have also been
reported [103]. Oral l-carnitine showed a hepatoprotective effect due to a decrease in the levels of
gamma-glutamyltransferase, aspartate aminotransferase, and alanine aminotransferase [104].
l-carnitine supplementation in elderly hemodialyzed patients with end-stage kidney disorder
increased amino acid metabolism, fatty acid metabolism, blood acy l-carnitine levels, and energy
production in skeletal and heart muscles [105]. Others found 50 mg/kg l-carnitine for 6 to 10 months
in children treated with hemodialysis pediatric at 18 years of age by reduction of parathyroid hormone
level, which led to maintained bone density and decreased bone resorption [106]. In one study, in
pediatric peritoneal dialysis, patients observed reduction of apolipoprotein B levels with 50 mg/kg per
day of l-carnitine supplementation for a month [107]. Sheikhi et al. [108] found no change in Apo AI
and SB100 levels following use of l-carnitine. One study outlined the great risk of carnitine deficiency:
carnitine insufficiency and the prevalence of carnitine deficiency were estimated at 73.5%, 82.3% and
8.8% among dialyzed patients, respectively [109]. l-carnitine displayed a cardioprotective function
in women after six months, increasing d-loop methylation in platelets and reducing the low-density
lipoprotein cholesterol level and trimethylamine-N-oxide level [110]. Bavbek et al. [111] reported that
the use of carnitine (20 mg/kg) three times a week for six months in chronic hemodialyzed patients
could increase total and free carnitine levels by improving forced expiratory volume in one second and
forced vital capacity, leading to management of respiratory dysfunction.
Patients with phenylketonuria receiving l-carnitine (98 mg/day) combined with selenium
(31.5 micrograms/day) for six months showed the restoration of GSH-Px activity, and the improvement
of protein and lipid oxidative damage [112]. Chromium picolinate (at a dose of 200 µg/day) combined
with carnitine (1000 µg/day) in women with polycystic ovary syndrome for 12 weeks showed a
significant improvement of stress, depression, and anxiety [113].
Administration of l-carnitine in patients with maple syrup urine disease prevented DNA damage
induced by alloisoleucine, branched-chain α-keto-acids and branched-chain amino acids [114]. In a
study by Cruciani et al. [115], patients affected by cancer with carnitine deficiency-induced fatigue
received l-carnitine (3000 mg/day) for a week, and showed a significant improvement, enhancing total
and free carnitine without any toxicity or complications. Use of l-carnitine (4 g/day) for three months
in patients with advanced pancreatic cancer improved quality of life and nutritional status [116].
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In a study by Shirali et al. [117], male teen soccer players received carnitine (2 g/day) combined
with caffeine (6 mg/kg/day) and showed a reduction in body weight and body fat percentage by
increasing lipolysis. Use of l-carnitine (250 mg) for 12 weeks in patients with polycystic ovary syndrome
reduced hip and waist circumference, body mass index, and weight [118]. In a study conducted in
Libia by Ibrahim et al., 1000-mg l-carnitine supplementation twice a day for three months in type
2 diabetic patients with dyslipidemia reduced triglyceride levels, but did not change low-density
lipoprotein-cholesterol, high-density cholesterol lipoprotein or total cholesterol levels [119].
Moradi et al. [120] improved idiopathic male infertility through the administration of clomiphene
citrate and carnitine, so that their patients receiving carnitine (25 mg/day) showed an increase
in semen volume and those receiving clomiphene citrate (2 g/day) showed an improvement in
morphology and motility. In another study, patients with chronic hepatitis C virus infection who
received l-carnitine (2 g twice a day) combined with ribavirin (800 mg/day) for 12 months showed an
improvement in sustained virological response and modulation of thrombocytopoiesis, leucopoiesis
and erythropoiesis [121]. The use of l-carnitine (50 mg/kg/day) in patients with maple syrup urine
disease for two months diminished DNA damage index [122].
3. Carnitine-Based Dietary Supplements
Nowadays, food supplements field is certainly varied and growing: a great range of new products
are launched on the market every year. This is reflected in a new reorganization of drugs leading
to changes in dietary supplement regulations [123–136]. Dietary supplements are made by mixing
biologically active substances intended for consumption with food or as an addition to food products,
with the purpose of optimizing metabolic processes and human body functions. Dietary supplements
include, mainly, micronutrients, e.g., vitamins, trace elements, amino acids and enzymes, but also
proteins, probiotics and oils, which can provide antioxidant, detoxifying, immunomodulatory and
adaptogenic effects, etc.
Virji, in a 2017 study [137], remarked on the potential benefits of l-carnitine as dietary supplement.
There is a growing body of outcomes data that demonstrates the beneficial effects of l-carnitine
in the treatment of coronary artery disease, metabolic syndrome, and obesity. Odle et al., in 2014,
reported how the l-isomer can be synthesized, and, consequently, high-purity dietary supplements are
commercially available and are generally recognized as safe [14].
3.1. Monitoring l-Carnitine in Dietary Supplements
In the context of dietary supplements, detection of physiologically active components represents
a difficult task and requires the use of modern highly informative research methods. Some studies
describing this methodological approach to l-carnitine in dietary supplements are reported in the
following. De Andrés et al. [138] proposed achiral liquid chromatography with circular dichroism
detection for the determination of carnitine enantiomers in dietary supplements and pharmaceutical
formulations [138]. Sánchez-Hernández et al. [139] developed a method for simultaneous and
simple unequivocal identification and determination of carnitine enantiomers in dietary food
supplements by capillary electrophoresis–electrospray ionization–tandem mass spectrometry [139].
Isaguirre et al. [140] proposed a new flow injection method for quality control of dietary supplements
containing l-carnitine using an extraction mediated by sodium taurodeoxycholate coacervate coupled
to molecular fluorescence [140]. A recent work of Voitiuk et al. [141] proposed a simple, rapid and
selective method for determining ascorbic acid and l-carnitine l-tartrate in a multicomponent dietary
supplement, produced in the form of sachets, using HPLC with spectrophotometric detection [141].
Ellingson et al. used LC-MS/MS-based analysis to measure total and free carnitine levels, so that
acid-assisted microwave hydrolysis and water extraction were employed to analyze total and free
analysis respectively. Their results showed overall RSD with intermediate precision of 3.1% and 3.3%
and an overall repeatability of 2.7% and 2.9% for total and free carnitine levels, respectively [142].
Johnson et al. applied LC-MS/MS analysis to measure the plasma levels of total and free carnitine.
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Acetonitrile 0.3% formic acid was used to extract the total carnitine and to avoid the time-consuming
step of salt elimination, and acid hydrolysis was utilized instead of base hydrolysis to quantify the total
carnitine level [143]. The LOQ and LOD values were 2.54 and 1.79 µmol/L for the total carnitine and
1.36 and 0.87 µmol/L for the free carnitine. The varying analytical techniques used seem to indicate
that the monitoring can be achieved by using different techniques but also that more in-depth studies
are needed to identify a unique method of analysis which can guarantee efficient monitoring of the
amount of the active components present in a food supplement.
3.2. A Shot of Dietary Supplement Label Databases
Considering the relevance of dietary supplements in the evaluation of total dietary intake,
remarked on during the National Health and Nutrition Examination Survey (NHANES), a dietary
supplement label database [144,145] was launched in 2013 by the Academy of Nutrition and Dietetics
in the United States: this contains label information (brand name, ingredients, amount per serving, and
manufacturer contact information) on more than 71,000 dietary supplements present and consumed
in the U.S. marketplace [144,146–148]. The dietary supplement label database (DSLD) can be used to
track changes in product composition and capture new products entering the market, representing a
useful tool for consumers, professionals, and researchers, useful for multiple applications [144,147].
For example, by searching in DSLD [146] by product/brand name, and typing “carnitine” as a keyword,
research has identified 434 products.
Recently, at European level, information on the compositions reported on labels of selected
dietary supplements has been collected and updated for the development of a DSLD according to
products’ availability on the Italian market, also including items consumed in the last Italian Dietary
Survey [149,150]: a total of 558 products have been entered into the database as of December 2019. This
aims to give a uniform image and representation of the major classes of food supplements consumed
in Italy. It is important to underline that, for each item, a code was assigned following the food
classification system FoodEx2 developed by EFSA [151], to allow standardization and harmonization
of the data among different countries.
In particular, DSLD in Italy reported the codes for seven carnitine-based products, classifying,
with a base term [A03SC] Carnitine or creatine-based supplements for sports-practicing individuals.
Carnitine is also present as an ingredient in Mixed supplements/formulations [A03TC] as well as in
Micronutrient supplements for sports people [A03SB] groups.
4. Conclusions and Future Remarks
This perspective paper offers an updated overview of the nutraceutical value of carnitine and its
use in dietary supplements. The beneficial health effects observed are many.
Nonetheless, the use of carnitine as dietary supplement should be regulated to avoid overdosage.
Some studies show a possible onset of side effects related to carnitine supplements. These unwanted
effects include sporadic vomiting and diarrhea, as observed in children with autism spectrum
disorder when administered high doses of carnitine, e.g., 400 mg/kg/day [152]. The recent review by
Malaguarnera and Cauli [153], summarizing the effects of l-carnitine in patients with autism spectrum
disorders, reported that doses of about 50–100 mg/kg/day are generally well tolerated, whereas side
effects observed with a dose of 200 mg/kg/day resulted in gastro-intestinal symptoms and a strong,
unpleasant skin odor. An effect of dietary l-carnitine has been recently reported on the metabolism of
gut microbiota, increasing TMAO (trimethylamine-N-oxide) and TMA (trimethylamine) and resulting
in possible cardio-metabolic risk [154–158]. On the other hand, a recent meta-analysis published by
Asadi et al. [159] showed that l-carnitine supplementation could be effective in maintaining lipid
profile levels, particularly in doses higher than 1500 mg/day, even if more RCTs with large sample
sizes, focusing on gut microbiome profiles and dietary patterns, are needed. The limited number of
clinical trials evaluating the effects of carnitine the human health seems to emphasize the need for and
importance of further research in this field.
Molecules 2020, 25, 2127 11 of 19
Author Contributions: A.D. and A.S. conceived and designed the work. A.D., M.L., A.N., E.B.S. and A.S. wrote
the work. A.N., S.B.S., A.M.S., M.L., and P.S. validated and elaborated data information and figures. A.D., M.L.,
A.N., S.S., A.M.S., P.S., E.B.S., and A.S. made a substantial contribution to the revision of work and approved it for
publication. All authors have read and agreed to the published version of the manuscript.
Funding: The authors acknowledge the support of the research project: Nutraceutica come supporto nutrizionale
nel paziente oncologico, CUP: B83D18000140007. E. B. Souto acknowledges the sponsorship of the projects
M-ERA-NET-0004/2015-PAIRED and UIDB/04469/2020 (strategic fund), A.M.S. the UID/AGR/04033/2019 (CITAB),
receiving support from the Portuguese Science and Technology Foundation, Ministry of Science and Education
(FCT/MEC) through national funds, and co-financed by FEDER, under the Partnership Agreement PT2020.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Alesci, S. Carnitine: The science behind a conditionally essential nutrient. Ann. N. Y. Acad. Sci. 2004, 1033,
1–197.
2. Wolf, G. The discovery of a vitamin role for carnitine: The first 50 years. J. Nutr. 2006, 136, 2131–2134.
[CrossRef] [PubMed]
3. Sharma, S.; Black, S.M. Carnitine homeostasis, mitochondrial function and cardiovascular disease.
Drug Discov. Today 2009, 6, e31–e39. [CrossRef] [PubMed]
4. Marcovina, S.M.; Sirtori, C.; Peracino, A.; Gheorghiade, M.; Borum, P.; Remuzzi, G.; Ardehali, H. Translating
the basic knowledge of mitochondrial functions to metabolic therapy: Role of l-carnitine. Transl. Res. 2013,
161, 73–84. [CrossRef]
5. El-Hattab, A.W.; Scaglia, F. Disorders of carnitine biosynthesis and transport. Mol. Genet. Metab. 2015, 116,
107–112. [CrossRef]
6. Longo, N.; Amat di San Filippo, C.; Pasquali, M. Disorders of carnitine transport and the carnitine cycle.
Am. J. Med. Genet. 2006, 142, 77–85. [CrossRef]
7. Wang, L.Y.; Chen, N.I.; Chen, P.W.; Chiang, S.C.; Hwu, W.L.; Lee, N.C.; Chien, Y.H. Newborn screening for
citrin deficiency and carnitine uptake defect using second-tier molecular tests. BMC Med. Genet. 2013, 14, 24.
[CrossRef]
8. Chen, Y.C.; Chien, Y.H.; Chen, P.W.; Leung-Sang Tang, N.; Chiu, P.C.; Hwu, W.L.; Lee, N.C. Carnitine uptake
defect (primary carnitine deficiency): Risk in genotype-phenotype correlation. Hum. Mutat. 2013, 34, 655.
[CrossRef]
9. Lee, N.C.; Tang, N.L.S.; Chien, Y.H.; Chen, C.A.; Lin, S.J.; Chiu, P.C.; Huang, A.C.; Hwu, W.L. Diagnoses of
newborns and mothers with carnitine uptake defects through newborn screening. Mol. Genet. Metabol. 2010,
100, 46–50. [CrossRef]
10. Longo, N.; Frigeni, M.; Pasquali, M. Carnitine transport and fatty acid oxidation. Biochem. Biophys. Acta
2016, 1863, 2422–2435. [CrossRef]
11. Steiber, A.; Kerner, J.; Hoppel, C.L. Carnitine: A nutritional, biosynthetic, and functional perspective.
Mol. Aspects Med. 2004, 25, 455–473. [CrossRef] [PubMed]
12. Reuter, S.E.; Evans, A.M. Carnitine and acylcarnitines. Clin. Pharmacokin. 2012, 51, 553–572. [CrossRef]
[PubMed]
13. Pormsila, W.; Krähenbühl, S.; Hauser, P.C. Determination of carnitine in food and food supplements
by capillary electrophoresis with contactless conductivity detection. Electrophoresis 2010, 31, 2186–2191.
[CrossRef] [PubMed]
14. Odle, J.; Adams, S.H.; Vockley, J. Carnitine. Adv. Nutr. 2014, 5, 289–290. [CrossRef] [PubMed]
15. Flanagan, J.L.; Simmons, P.A.; Vehige, J.; Willcox, M.D.; Garrett, Q. Role of carnitine in disease. Nutr. Metabol.
2010, 7, 30. [CrossRef]
16. Ribas, G.S.; Vargas, C.R.; Wajner, M. l-carnitine supplementation as a potential antioxidant therapy for
inherited neurometabolic disorders. Gene 2014, 533, 469–476. [CrossRef]
17. Xu, Y.; Jiang, W.; Chen, G.; Zhu, W.; Ding, W.; Ge, Z.; Tan, Y.; Ma, T.; Cui, G. l-carnitine treatment of insulin
resistance: A systematic review and meta-analysis. Adv. Clin. Exper. Med. 2017, 26, 333–338. [CrossRef]
18. DiNicolantonio, J.J.; Lavie, C.J.; Fares, H.; Menezes, A.R.; O’Keefe, J.H. l-carnitine in the secondary prevention
of cardiovascular disease: Systematic review and meta-analysis. Proc. Mayo Clin. Proc. 2013, 88, 544–551.
[CrossRef]
Molecules 2020, 25, 2127 12 of 19
19. Shang, R.; Sun, Z.; Li, H. Effective dosing of l-carnitine in the secondary prevention of cardiovascular disease:
A systematic review and meta-analysis. BMC Cardiovasc Disord. 2014, 14, 88. [CrossRef]
20. Melone, M.A.B.; Valentino, A.; Margarucci, S.; Galderisi, U.; Giordano, A.; Peluso, G. The carnitine system
and cancer metabolic plasticity. Cell Death Dis. 2018, 9, 1–12. [CrossRef]
21. Hathcock, J.N.; Shao, A. Risk assessment for carnitine. Regul. Toxicol. Pharmacol. 2006, 46, 23–28. [CrossRef]
[PubMed]
22. Ribas, G.S.; Manfredini, V.; de Marco, M.G.; Vieira, R.B.; Wayhs, C.Y.; Vanzin, C.S.; Biancini, G.B.; Wajner, M.;
Vargas, C.R. Prevention by l-carnitine of DNA damage induced by propionic and L-methylmalonic acids
in human peripheral leukocytes in vitro. Mutat. Res. Genet Toxicol. Environ. Mutagen. 2010, 702, 123–128.
[CrossRef] [PubMed]
23. Banihani, S.; Sharma, R.; Bayachou, M.; Sabanegh, E.; Agarwal, A. Human sperm DNA oxidation, motility
and viability in the presence of l-carnitine during in vitro incubation and centrifugation. Andrologia 2012, 44,
505–512. [CrossRef] [PubMed]
24. Zamani, E.; Shokrzadeh, M.; Modanloo, M.; Shaki, F. In Vitro Study Towards Role of Acrylamide-Induced
Genotoxicity in Human Lymphocytes and the Protective Effect of l-carnitine. Braz Arch Bio Technol. 2018, 61.
[CrossRef]
25. Hua, X.; Deng, R.; Li, J.; Chi, W.; Su, Z.; Lin, J.; Pflugfelder, S.C.; Li, D.-Q. Protective effects of l-carnitine
against oxidative injury by hyperosmolarity in human corneal epithelial cells. Investig. Ophthal. Visual Sci.
2015, 56, 5503–5511. [CrossRef]
26. Farahzadi, R.; Fathi, E.; Mesbah-Namin, S.A.; Zarghami, N. Anti-aging protective effect of l-carnitine as
clinical agent in regenerative medicine through increasing telomerase activity and change in the hTERT
promoter CpG island methylation status of adipose tissue-derived mesenchymal stem cells. Tissue Cell. 2018,
54, 105–113. [CrossRef]
27. Nakamura, Y.; Iida, H.; Nakatake, R.; Sakaguchi, T.; Kaibori, M.; Okumura, T.; Hamada, Y.; Doi, T. l-carnitine
has a liver-protective effect through inhibition of inducible nitric oxide synthase induction in primary
cultured rat hepatocytes. Funct. Foods Health Dis. 2018, 8, 212–227. [CrossRef]
28. Baci, D.; Bruno, A.; Bassani, B.; Tramacere, M.; Mortara, L.; Albini, A.; Noonan, D.M. Acetyl-l-carnitine
is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways. Cancer Lett. 2018, 429, 100–116.
[CrossRef]
29. Fernandes, S.; Salta, S.; Bravo, J.; Silva, A.; Summavielle, T. Acetyl-l-carnitine prevents methamphetamine-
induced structural damage on endothelial cells via ILK-related MMP-9 activity. Mol. Neurobiol. 2016, 53,
408–422. [CrossRef]
30. Singh, M.; Miura, P.; Renden, R. Age-related defects in short-term plasticity are reversed by acetyl-l-carnitine
at the mouse calyx of Held. Neurobiol. Aging. 2018, 67, 108–119. [CrossRef]
31. Nicassio, L.; Fracasso, F.; Sirago, G.; Musicco, C.; Picca, A.; Marzetti, E.; Calvani, R.; Cantatore, P.;
Gadaleta, M.N.; Pesce, V. Dietary supplementation with acetyl-l-carnitine counteracts age-related alterations
of mitochondrial biogenesis, dynamics and antioxidant defenses in brain of old rats. Exp. Gerontol. 2017, 98,
99–109. [CrossRef] [PubMed]
32. Muoio, D.M.; Noland, R.C.; Kovalik, J.P.; Seiler, S.E.; Davies, M.N.; DeBalsi, K.L.; Ilkayeva, O.R.; Stevens, R.D.;
Kheterpal, I.; Zhang, J. Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance
and metabolic flexibility. Cell Metabol. 2012, 15, 764–777. [CrossRef] [PubMed]
33. Abdelkarem, H.M.; Fadda, L.H.; Hassan, A.A. Potential intervention of α-Lipoic acid and carnitine on insulin
sensitivity and anti-inflammatory cytokines levels in fructose-fed rats, a model of metabolic syndrome.
J. Diet. Suppl. 2017, 14, 54–64. [CrossRef] [PubMed]
34. Bodaghi-Namileh, V.; Sepand, M.R.; Omidi, A.; Aghsami, M.; Seyednejad, S.A.; Kasirzadeh, S.; Sabzevari, O.
Acetyl-l-carnitine attenuates arsenic-induced liver injury by abrogation of mitochondrial dysfunction,
inflammation, and apoptosis in rats. Environ. Toxicol. Pharmacol. 2018, 58, 11–20. [CrossRef] [PubMed]
35. Edres, H.A.; Taha, N.M.; Mandour, A.E.W.A.; Lebda, M.A. Impact of l-carnitine on Bisphenol A-Induced
Kidney Damage in Rats. Alex. J. Vet. Sci. 2018, 56, 11–17. [CrossRef]
36. Al-Eisa, R.A.; Al-Salmi, F.A.; Hamza, R.Z.; El-Shenawy, N.S. Role of l-carnitine in protection against the
cardiac oxidative stress induced by aspartame in Wistar albino rats. PLoS ONE 2018, 13, e0204913. [CrossRef]
[PubMed]
Molecules 2020, 25, 2127 13 of 19
37. Couturier, A.; Ringseis, R.; Mooren, F.C.; Krüger, K.; Most, E.; Eder, K. Carnitine supplementation to obese
Zucker rats prevents obesity-induced type I to type II muscle fiber transition and favors an oxidative
phenotype of skeletal muscle. Nutr. Metab. 2013, 10, 48. [CrossRef]
38. Ahmed, M.M.; Ibrahim, Z.S.; Alkafafy, M.; El-Shazly, S.A. l-carnitine protects against testicular dysfunction
caused by gamma irradiation in mice. Acta histochemica 2014, 116, 1046–1055. [CrossRef]
39. Kim, J.H.; Pan, J.H.; Lee, E.S.; Kim, Y.J. l-carnitine enhances exercise endurance capacity by promoting
muscle oxidative metabolism in mice. Biochem. Biophys. Res. Commun. 2015, 464, 568–573. [CrossRef]
40. Meky, N.H.; Haggag, A.M.; Kamal, A.M.; Ahmed, Z.A. The Protective Effect of l-carnitine against Gamma
Irradiation-Induced Cardiotoxicity in Male Albino Rats. Egypt. Acad. J. Bio. Sci. Phys. Mol. Bio. 2017, 9, 9–20.
[CrossRef]
41. Sepand, M.R.; Razavi-Azarkhiavi, K.; Omidi, A.; Zirak, M.R.; Sabzevari, S.; Kazemi, A.R.; Sabzevari, O.
Effect of acetyl-l-carnitine on antioxidant status, lipid peroxidation, and oxidative damage of arsenic in rat.
Biol. Trace Elem. Res. 2016, 171, 107–115. [CrossRef] [PubMed]
42. Jang, J.; Park, J.; Chang, H.; Lim, K. l-carnitine supplement reduces skeletal muscle atrophy induced by
prolonged hindlimb suspension in rats. Appl. Physiol. Nutr. Metab. 2016, 41, 1240–1247. [CrossRef] [PubMed]
43. Collins, H.L.; Drazul-Schrader, D.; Sulpizio, A.C.; Koster, P.D.; Williamson, Y.; Adelman, S.J.; Owen, K.;
Sanli, T.; Bellamine, A. l-carnitine intake and high trimethylamine N-oxide plasma levels correlate with
low aortic lesions in ApoE−/− transgenic mice expressing CETP. Atherosclerosis 2016, 244, 29–37. [CrossRef]
[PubMed]
44. Canbolat, E.P.; Sagsoz, N.; Noyan, V.; Yucel, A.; Kısa, U. Effects of l-carnitine on oxidative stress parameters
in oophorectomized rats. Alex. Med. J. 2017, 53, 55–60. [CrossRef]
45. Zamani, E.; Shokrzadeh, M.; Ziar, A.; Abedian-Kenari, S.; Shaki, F. Acrylamide attenuated immune tissues’
function via induction of apoptosis and oxidative stress: Protection by l-carnitine. Hum. Exp. Toxicol. 2018,
37, 859–869. [CrossRef]
46. Zakzok, F.B.; Hegazy, H.M.; Yosef, T.A.; Gomaa, G.M. Mitigating impact of l-carnitine against dimethoate
induction of hepatic and testicular genotoxicity in rats: The role of oxidative stress. Toxin Rev. 2018.
[CrossRef]
47. Salama, S.A.; Arab, H.H.; Omar, H.A.; Gad, H.S.; Abd-Allah, G.M.; Maghrabi, I.A. l-carnitine mitigates
UVA-induced skin tissue injury in rats through downregulation of oxidative stress, p38/c-Fos signaling, and
the proinflammatory cytokines. Chem.-Biol. Interact. 2018, 285, 40–47. [CrossRef]
48. Cruz, W.M.S.; Guimaraes, S.; Maciel, G.C.; Huguenin, A.B.A.; Carvalho, M.E.D.; Costa, B.O.; Silva, G.A.;
Colafranceschi, A.S.; Scalco, F.B.; Ribeiro, M. l-carnitine supplementation in the recovery of plasma l-carnitine
in patients with heart failure submitted to coronary artery bypass grafting. Anais da Acad. Bras. de Ciências
2018, 90, 3099–3104. [CrossRef]
49. Yaghubi, E.; Daneshpazhooh, M.; Djalali, M.; Mohammadi, H.; Sepandar, F.; Fakhri, Z.; Ghaedi, E.;
Keshavarz, S.A.; Balighi, K.; Mahmoudi, H. Effects of l-carnitine supplementation on cardiovascular and
bone turnover markers in patients with pemphigus vulgaris under corticosteroids treatment: A randomized,
double-blind, controlled trial. Dermat. Therap. 2019, 32, e13049. [CrossRef]
50. Talari, H.R.; Azad, Z.J.; Hamidian, Y.; Samimi, M.; Gilasi, H.R.; Afshar, F.E.; Ostadmohammadi, V.; Asemi, Z.
Effects of carnitine administration on carotid intima-media thickness and inflammatory factors in patients
with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Int. J. Prev. Med.
2019, 10, 89.
51. Ravikumar, S.; Prabhu, S.; Vani, R. Effects of l-carnitine on the erythrocytes of stored human blood.
Transfus. Med. 2019, 8. [CrossRef] [PubMed]
52. Mohammadi, M.; Talasaz, A.H.; Alidoosti, M. Preventive effect of l-carnitine and its derivatives on endothelial
dysfunction and platelet aggregation. Clin. Nutr. ESPEN 2016, 15, 1–10. [CrossRef] [PubMed]
53. Guerreiro, G.; Faverzani, J.; Jacques, C.E.D.; Marchetti, D.P.; Sitta, A.; de Moura Coelho, D.; Kayser, A.;
Kok, F.; Athayde, L.; Manfredini, V. Oxidative damage in glutaric aciduria type I patients and the protective
effects of l-carnitine treatment. J. Cell. Biochem. 2018, 119, 10021–10032. [CrossRef] [PubMed]
54. Gnoni, A.; Longo, S.; Gnoni, G.V.; Giudetti, A.M. Carnitine in Human Muscle Bioenergetics: Can Carnitine
Supplementation Improve Physical Exercise? Molecules 2020, 25, 182. [CrossRef] [PubMed]
Molecules 2020, 25, 2127 14 of 19
55. Kitano, Y.; Hashimoto, S.; Matsumoto, H.; Yamochi, T.; Yamanaka, M.; Nakaoka, Y.; Fukuda, A.; Inoue, M.;
Ikeda, T.; Morimoto, Y. Oral administration of l-carnitine improves the clinical outcome of fertility in patients
with IVF treatment. Gynecol. Endocr. 2018, 34, 684–688. [CrossRef] [PubMed]
56. Verrina, E.; Caruso, U.; Calevo, M.G.; Emma, F.; Sorino, P.; De Palo, T.; Lavoratti, G.; Dertenois, L.T.;
Cassanello, M.; Cerone, R. Effect of carnitine supplementation on lipid profile and anemia in children on
chronic dialysis. Ped. Neph. 2007, 22, 727–733. [CrossRef]
57. Geier, D.A.; Kern, J.K.; Davis, G.; King, P.G.; Adams, J.B.; Young, J.L.; Geier, M.R. A prospective double-blind,
randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med. Sci. Monit. 2011, 17, PI15.
[CrossRef]
58. Fahmy, S.F.; El-hamamsy, M.H.; Zaki, O.K.; Badary, O.A. l-carnitine supplementation improves the behavioral
symptoms in autistic children. Res. Autism Spect. Disord. 2013, 7, 159–166. [CrossRef]
59. Ziats, M.N.; Comeaux, M.S.; Yang, Y.; Scaglia, F.; Elsea, S.H.; Sun, Q.; Beaudet, A.L.; Schaaf, C.P. Improvement
of regressive autism symptoms in a child with TMLHE deficiency following carnitine supplementation.
Am. J. Med. Genet. A. 2015, 167, 2162–2167. [CrossRef]
60. Roy, M.J.; Dionne, S.; Marx, G.; Qureshi, I.; Sarma, D.; Levy, E.; Seidman, E.G. In vitro studies on the inhibition
of colon cancer by butyrate and carnitine. Nutrition 2009, 25, 1193–1201. [CrossRef]
61. Baci, D.; Bruno, A.; Cascini, C.; Gallazzi, M.; Mortara, L.; Sessa, F.; Pelosi, G.; Albini, A.; Noonan, D.M.
Acetyl-l-carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8)
pathways in prostate cancer cells: Rationale for prevention and interception strategies. J. Exp. Clin. Cancer Res.
2019, 38, 464. [CrossRef] [PubMed]
62. Huang, H.; Liu, N.; Guo, H.; Liao, S.; Li, X.; Yang, C.; Liu, S.; Song, W.; Liu, C.; Guan, L. l-carnitine is an
endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. PLoS ONE 2012,
7, e49062. [CrossRef] [PubMed]
63. Zhang, R.; Zhang, H.; Zhang, Z.; Wang, T.; Niu, J.; Cui, D.; Xu, S. Neuroprotective effects of pre-treatment
with l-carnitine and acetyl-l-carnitine on ischemic injury in vivo and in vitro. Int. J. Mol. Sci. 2012, 13,
2078–2090. [CrossRef] [PubMed]
64. Deon, M.; Landgraf, S.S.; Lamberty, J.F.; Moura, D.J.; Saffi, J.; Wajner, M.; Vargas, C.R. Protective effect of
l-carnitine on Phenylalanine-induced DNA damage. Metab. Brain Dis. 2015, 30, 925–933. [CrossRef]
65. Kocsis, K.; Frank, R.; Szabó, J.; Knapp, L.; Kis, Z.; Farkas, T.; Vécsei, L.; Toldi, J. Acetyl-l-carnitine
restores synaptic transmission and enhances the inducibility of stable LTP after oxygen–glucose deprivation.
Neuroscience 2016, 332, 203–211. [CrossRef]
66. Bavari, M.; Tabandeh, M.R.; Najafzadeh Varzi, H.; Bahramzadeh, S. Neuroprotective, antiapoptotic and
antioxidant effects of l-carnitine against caffeine-induced neurotoxicity in SH-SY5Y neuroblastoma cell line.
Drug Chem. Toxicol. 2016, 39, 157–166. [CrossRef]
67. de Moraes, M.S.; Guerreiro, G.; Sitta, A.; de Moura Coelho, D.; Manfredini, V.; Wajner, M.; Vargas, C.R.
Oxidative damage in mitochondrial fatty acids oxidation disorders patients and the in vitro effect of
l-carnitine on DNA damage induced by the accumulated metabolites. Arch. Biochem. Biophys. 2020,
679, 108206. [CrossRef]
68. Montesano, A.; Senesi, P.; Vacante, F.; Mollica, G.; Benedini, S.; Mariotti, M.; Luzi, L.; Terruzzi, I.
l-carnitine counteracts in vitro fructose-induced hepatic steatosis through targeting oxidative stress markers.
J. Endocrinol. Investig. 2019, 43, 493–503. [CrossRef]
69. Terruzzi, I.; Montesano, A.; Senesi, P.; Villa, I.; Ferraretto, A.; Bottani, M.; Vacante, F.; Spinello, A.;
Bolamperti, S.; Luzi, L. l-carnitine reduces oxidative stress and promotes cells differentiation and bone
matrix proteins expression in human osteoblast-like cells. BioMed. Res. Int. 2019, 2019, 5678548. [CrossRef]
70. Calandrella, N.; De Seta, C.; Scarsella, G.; Risuleo, G. Carnitine reduces the lipoperoxidative damage of the
membrane and apoptosis after induction of cell stress in experimental glaucoma. Cell Death Dis. 2010, 1, e62.
[CrossRef]
71. Farahzadi, R.; Mesbah-Namin, S.A.; Zarghami, N.; Fathi, E. l-carnitine effectively induces hTERT gene
expression of human adipose tissue-derived mesenchymal stem cells obtained from the aged subjects. Int. J.
Stem Cells. 2016, 9, 107. [CrossRef] [PubMed]
Molecules 2020, 25, 2127 15 of 19
72. Rodrigues, D.G.B.; de Moura Coelho, D.; Sitta, Â.; Jacques, C.E.D.; Hauschild, T.; Manfredini, V.;
Bakkali, A.; Struys, E.A.; Jakobs, C.; Wajner, M. Experimental evidence of oxidative stress in patients
with l-2-hydroxyglutaric aciduria and that l-carnitine attenuates in vitro DNA damage caused by
d-2-hydroxyglutaric and l-2-hydroxyglutaric acids. Toxicol. Vitro 2017, 42, 47–53. [CrossRef] [PubMed]
73. Le Borgne, F.; Ravaut, G.; Bernard, A.; Demarquoy, J. l-carnitine protects C2C12 cells against mitochondrial
superoxide overproduction and cell death. World J. Biol. Chem. 2017, 8, 86. [CrossRef] [PubMed]
74. Al-Shammari, M.H.M.; Yenzeel, J.H.; Fakhrildin, M.-B.M. Effect of l-carnitine and COQ10 addition to SMART
Pro-medium on human sperm concentration, sperm morphology and chromatin structure during in vitro
sperm activation. J. Pharm. Bio. Sci. 2017, 12, 51–55.
75. Abdel-Emam, R.A.; Ahmed, E.A.; Ali, M.F. The protective role of l-carnitine against 1st- and 2nd-generation
antihistamine-induced liver injury in mice. Compar. Clin. Path. 2020, 29, 213–221. [CrossRef]
76. Ahmed, E.A.; Abd-Eldayem, A.M.; Aboulhagag, N.A. The possible protective effects of vitamin D and
l-carnitine against used atorvastatin-induced myopathy and hepatotoxicity. Compar. Clin. Path. 2019, 28,
1751–1759. [CrossRef]
77. Salic, K.; Gart, E.; Seidel, F.; Verschuren, L.; Caspers, M.; van Duyvenvoorde, W.; Wong, K.E.; Keijer, J.;
Bobeldijk-Pastorova, I.; Wielinga, P.Y. Combined Treatment with l-carnitine and Nicotinamide Riboside
Improves Hepatic Metabolism and Attenuates Obesity and Liver Steatosis. Int. J. Mol. Sci. 2019, 20, 4359.
[CrossRef]
78. Ali, S.A.; Faddah, L.; Abdel-Baky, A.; Bayoumi, A. Protective effect of l-carnitine and coenzyme Q10 on
CCl4-induced liver injury in rats. Sci. Pharm. 2010, 78, 881–896. [CrossRef]
79. Dobrzyn´ska, I.; Szachowicz-Petelska, B.; Skrzydlewska, E.; Figaszewski, Z. Effect of l-carnitine on liver cell
membranes in ethanol-intoxicated rats. Chem.-Bio. Interact. 2010, 188, 44–51. [CrossRef]
80. Xiang, Y.; Piao, S.; Zou, H.; Jin, J.; Fang, M.; Lei, D.; Gao, B.; Yang, C.; Li, C. l-carnitine protects against
cyclosporine-induced pancreatic and renal injury in rats. Transpl. Proc. 2013, 45, 3127–3134. [CrossRef]
81. Ishikawa, H.; Takaki, A.; Tsuzaki, R.; Yasunaka, T.; Koike, K.; Shimomura, Y.; Seki, H.; Matsushita, H.;
Miyake, Y.; Ikeda, F. l-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with
upregulation of mitochondrial pathway. PLoS ONE 2014, 9, e100627. [CrossRef] [PubMed]
82. Wang, S.; Xu, J.; Zheng, J.; Zhang, X.; Shao, J.; Zhao, L.; Hao, J. Anti-Inflammatory and Antioxidant Effects of
Acetyl-l-carnitine on Atherosclerotic Rats. Med. Sci. Monit. 2020, 26, e920250. [CrossRef] [PubMed]
83. Blanca, A.J.; Ruiz-Armenta, M.V.; Zambrano, S.; Miguel-Carrasco, J.L.; Arias, J.L.; Arevalo, M.; Mate, A.;
Aramburu, O.; Vazquez, C.M. Inflammatory and fibrotic processes are involved in the cardiotoxic effect of
sunitinib: Protective role of l-carnitine. Toxicol. Lett. 2016, 241, 9–18. [CrossRef] [PubMed]
84. Aziz, M.; Abd El Fattah, M.A.; Ahmed, K.A.; Moawad, H. Protective effects of Olmesartan and l-carnitine
on doxorubicin-induced Cardiotoxicity in rats. Can. J. Physiol. Pharmacol. 2019, 999, 183–193. [CrossRef]
[PubMed]
85. Lapi, D.; Sabatino, L.; Altobelli, G.G.; Mondola, P.; Cimini, V.; Colantuoni, A. Effects of propionyl-l-carnitine
on ischemia–reperfusion injury in hamster cheek pouch microcirculation. Front. Physiol. 2010, 1, 132.
[CrossRef] [PubMed]
86. Omori, Y.; Ohtani, T.; Sakata, Y.; Mano, T.; Takeda, Y.; Tamaki, S.; Tsukamoto, Y.; Kamimura, D.; Aizawa, Y.;
Miwa, T. l-carnitine prevents the development of ventricular fibrosis and heart failure with preserved
ejection fraction in hypertensive heart disease. J. Hypertens. 2012, 30, 1834–1844. [CrossRef]
87. Zambrano, S.; Blanca, A.J.; Ruiz-Armenta, M.V.; Miguel-Carrasco, J.L.; Arévalo, M.; Vázquez, M.J.; Mate, A.;
Vázquez, C.M. l-carnitine protects against arterial hypertension-related cardiac fibrosis through modulation
of PPAR-γ expression. Biochem. Pharmacol. 2013, 85, 937–944. [CrossRef]
88. Alharthi, W.A.; Hamza, R.Z.; Elmahdi, M.M.; Abuelzahab, H.S.H.; Saleh, H. Selenium and l-carnitine
Ameliorate Reproductive Toxicity Induced by Cadmium in Male Mice. Biol. Trace Elem. Res. 2019. [CrossRef]
89. Kelek, S.E.; Afs¸ar, E.; Akçay, G.; Danıs¸man, B.; Aslan, M. Effect of chronic l-carnitine supplementation
on carnitine levels, oxidative stress and apoptotic markers in peripheral organs of adult Wistar rats.
Food Chem. Toxicol. 2019, 134, 110851. [CrossRef]
90. Dokmeci, D.; Inan, M.; Basaran, U.N.; Yalcin, O.; Aydogdu, N.; Turan, F.N.; Uz, Y.H. Protective effect of
l-carnitine on testicular ischaemia–reperfusion injury in rats. Cell Biochem. Funct. Cellul. 2007, 25, 611–618.
[CrossRef]
Molecules 2020, 25, 2127 16 of 19
91. Boyacioglu, M.; Turgut, H.; Akgullu, C.; Eryilmaz, U.; Kum, C.; Onbasili, O.A. The efficient of l-carnitine on
oxidative stress responses of experimental contrast-induced nephropathy in rat. J. Vet. Med. Sci. 2014, 76,
13–0202. [CrossRef] [PubMed]
92. Abd-Elrazek, A.M.; Ahmed-Farid, O.A.H. Protective effect of l-carnitine and L-arginine against
busulfan-induced oligospermia in adult rat. Andrologia 2018, 50. [CrossRef] [PubMed]
93. Masoumi-Ardakani, Y.; Aminizadeh, S.; Fallah, H.; Shahouzehi, B. l-carnitine different doses affect serum
and pancreas tissue Antioxidative defense and histopathology in STZ-induced diabetic rats. Biologia 2020.
[CrossRef]
94. Hooshmand, S.; Balakrishnan, A.; Clark, R.M.; Owen, K.Q.; Koo, S.I.; Arjmandi, B.H. Dietary l-carnitine
supplementation improves bone mineral density by suppressing bone turnover in aged ovariectomized rats.
Phytomedicine 2008, 15, 595–601. [CrossRef] [PubMed]
95. Yuan, J.; Jiang, Q.; Song, L.; Liu, Y.; Li, M.; Lin, Q.; Li, Y.; Su, K.; Ma, Z.; Wang, Y.; et al. l-carnitine Is
Involved in Hyperbaric Oxygen-Mediated Therapeutic Effects in High Fat Diet-Induced Lipid Metabolism
Dysfunction. Molecules 2020, 25, 176. [CrossRef] [PubMed]
96. Chidiebere, U.; Ambali, S.F.; Ayo, J.O.; Eseivo, K.A. Acetyl-l-carnitine attenuates haemotoxicity induced by
subacute chlorpyrifos exposure in Wistar rats. Der. Pharm. Lettre. 2011, 3, 292–303.
97. Yarizadh, H.; Shab-Bidar, S.; Zamani, B.; Vanani, A.N.; Baharlooi, H.; Djafarian, K. The Effect of l-carnitine
Supplementation on Exercise-Induced Muscle Damage: A Systematic Review and Meta-Analysis of
Randomized Clinical Trials. J. Am. Coll. Nutr. 2020. [CrossRef]
98. Chae, H.; Ryu, M.-H.; Ma, J.; Beck, M.; Kang, Y.K. Impact of l-carnitine on imatinib-related muscle cramps in
patients with gastrointestinal stromal tumor. Investig. New Drugs. 2020, 38, 493–499. [CrossRef]
99. Malek Mahdavi, A.; Mahdavi, R.; Kolahi, S. Effects of l-carnitine Supplementation on Serum Inflammatory
Factors and Matrix Metalloproteinase Enzymes in Females with Knee Osteoarthritis: A Randomized,
Double-Blind, Placebo-Controlled Pilot Study. J. Am. Coll. Nutr. 2016, 35, 597–603. [CrossRef]
100. Kazemian, K.; Ala, S.; Mojtahedzadeh, M.; Abedini, M.; Alipour, A.; Abediankenari, S.; Rafati, M.;
Abaskhanidavanloo, A.; Mohajerani, F. Evaluation of neuroprotective effects of l-carnitine and Fat emulsion
in the CVA patients: A prospective, randomized, double blind, clinical trial. Iran. J. Pharm. Res. 2020, 19,
111–119. [CrossRef]
101. Di Stefano, G.; Di Lionardo, A.; Galosi, E.; Truini, A.; Cruccu, G. Acetyl- l-carnitine in painful peripheral
neuropathy: A systematic review. J. Pain Res. 2019, 12, 1341–1351. [CrossRef] [PubMed]
102. Abolfathi, M.; Mohd-Yusof, B.N.; Hanipah, Z.N.; Redzwan, S.M.; Yusof, L.M.; Khosroshahi, M.Z. The effects
of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease:
A systematic review and meta-analysis of randomized controlled trials. Complement. Ther. Med. 2019, 102273.
[CrossRef] [PubMed]
103. Thiagarajan, P.; Chalmers, J.; Ban, L.; Grindlay, D.; Aithal, G.P. l-carnitine supplementation in non-alcoholic
fatty liver disease: A systematic review and meta-analysis. WJMA 2020, 8, 4–14. [CrossRef]
104. Askarpour, M.; Djafarian, K.; Ghaedi, E.; Sadeghi, O.; Sheikhi, A.; Shab-Bidar, S. Effect of l-carnitine
Supplementation on Liver Enzymes: A Systematic Review and Meta-Analysis of Randomized Controlled
Trials. Arch. Med. Res. 2020, 51, 82–94. [CrossRef] [PubMed]
105. Kido, J.; Inoue, H.; Shimotsu, H.; Yoshida, Y.; Suzuki, Y.; Nakamura, K.; Endo, F.; Matsumoto, S. Effect of
l-carnitine on Amino Acid Metabolism in Elderly Patients Undergoing Regular Hemodialysis. Blood Purif.
2020. [CrossRef] [PubMed]
106. Safdar, O.; Jambi, G.; Asaad, O.; Hassan, L.; Al Dahlawi, L.; Halawani, A.F.; Jamjoom, M.; Shaikhoon, B.;
Azhar, A.; Zaher, Z.F. l-carnitine effect on bone disease in hemodialysis pediatric patients in KAU Hospital,
Jeddah Saudi Arabia: An experimental non-randomized study. Int. J. Med.Dev. Ctries. 2020, 4, 612–619.
[CrossRef]
107. Kos¸an, C.; Sever, L.; Arısoy, N.; Çalıs¸kan, S.; Kasapçopur, Ö. Carnitine supplementation improves
apolipoprotein B levels in pediatric peritoneal dialysis patients. Pediatr. Nephrol. 2003, 18, 1184–1188.
[CrossRef]
108. Sheikhi, A.; Djafarian, K.; Askarpour, M.; Shab-Bidar, S. The effects of supplementation with l-carnitine
on apolipoproteins: A systematic review and meta-analysis of randomized trials. Eur. J. Pharmacol. 2019,
858, 172493. [CrossRef]
Molecules 2020, 25, 2127 17 of 19
109. Shimizu, S.; Takashima, H.; Tei, R.; Furukawa, T.; Okamura, M.; Kitai, M.; Nagura, C.; Maruyama, T.;
Higuchi, T.; Abe, M. Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on
Peritoneal Dialysis. Nutrition 2019, 11, 2645. [CrossRef]
110. Bordoni, L.; Sawicka, A.K.; Szarmach, A.; Winklewski, P.J.; Olek, R.A.; Gabbianelli, R. A Pilot Study on the
Effects of l-carnitine and Trimethylamine-N-Oxide on Platelet Mitochondrial DNA Methylation and CVD
Biomarkers in Aged Women. Int. J. Mol. Sci. 2020, 21, 1047. [CrossRef]
111. Bavbek, N.; Akay, H.; Uz, B.; Uz, E.; Turgut, F.; Kanbay, M.; Senes, M.; Akcay, A.; Duranay, M. The effects
of l-carnitine therapy on respiratory function tests in chronic hemodialysis patients. Ren. Fail. 2010, 32,
157–161. [CrossRef] [PubMed]
112. Sitta, A.; Vanzin, C.S.; Biancini, G.B.; Manfredini, V.; De Oliveira, A.; Wayhs, C.; Ribas, G.; Giugliani, L.;
Schwartz, I.; Bohrer, D. Evidence that l-carnitine and selenium supplementation reduces oxidative stress in
phenylketonuric patients. Cellul. Mol. Neurobiol. 2011, 31, 429–436. [CrossRef] [PubMed]
113. Jamilian, M.; Foroozanfard, F.; Kavossian, E.; Aghadavod, E.; Amirani, E.; Mahdavinia, M.; Mafi, A.; Asemi, Z.
Carnitine and chromium co-supplementation affects mental health, hormonal, inflammatory, genetic, and
oxidative stress parameters in women with polycystic ovary syndrome. J. Psychosom. Obst. Gyn. 2019.
[CrossRef] [PubMed]
114. Hauschild, T.C.; Guerreiro, G.; Mescka, C.P.; Coelho, D.M.; Steffens, L.; Moura, D.J.; Manfredini, V.;
Vargas, C.R. DNA damage induced by alloisoleucine and other metabolites in maple syrup urine disease
and protective effect of l-carnitine. Toxicol. Vitro 2019, 57, 194–202. [CrossRef] [PubMed]
115. Cruciani, R.A.; Dvorkin, E.; Homel, P.; Malamud, S.; Culliney, B.; Lapin, J.; Portenoy, R.K.; Esteban-Cruciani, N.
Safety, tolerability and symptom outcomes associated with l-carnitine supplementation in patients with
cancer, fatigue, and carnitine deficiency: A phase I/II study. J. Pain Symptom Manag. 2006, 32, 551–559.
[CrossRef]
116. Kraft, M.; Kraft, K.; Gärtner, S.; Mayerle, J.; Simon, P.; Weber, E.; Schütte, K.; Stieler, J.; Koula-Jenik, H.;
Holzhauer, P. l-carnitine-supplementation in advanced pancreatic cancer (CARPAN)-a randomized
multicentre trial. Nutr. J. 2012, 11, 52. [CrossRef]
117. Shirali, S.; Daneghian, S.; Hosseini, S.A.; Ashtary-Larky, D.; Daneghian, M.; Mirlohi, M.-S. Effect of caffeine
co-ingested with carnitine on weight, body-fat percent, serum leptin and lipid profile changes in male teen
soccer players: A randomized clinical trial. Int. J. Pediat. 2016, 4, 3685–3698.
118. Samimi, M.; Jamilian, M.; Ebrahimi, F.A.; Rahimi, M.; Tajbakhsh, B.; Asemi, Z. Oral carnitine supplementation
reduces body weight and insulin resistance in women with polycystic ovary syndrome: A randomized,
double-blind, placebo-controlled trial. Clin. Endocrinol. 2016, 84, 851–857. [CrossRef]
119. Ibrahim, N.A.M.; Mansour, Y.S.E.; Sulieman, A.A.; Hussein, H.S. A Local Study on the Effects of L-carnitine
Supplement on Serum Lipid Profiles in Libyan Type 2 Diabetic Patients. IJARW 2020, 1, 28–32.
120. Moradi, M.; Moradi, A.; Alemi, M.; Ahmadnia, H.; Abdi, H.; Ahmadi, A.; Bazargan-Hejazi, S. Safety and
efficacy of clomiphene citrate and l-carnitine in idiopathic male infertility: A comparative study. Urol. J.
2010, 7, 188–193.
121. Malaguarnera, M.; Vacante, M.; Giordano, M.; Motta, M.; Bertino, G.; Pennisi, M.; Neri, S.; Malaguarnera, M.;
Volti, G.L.; Galvano, F. l-carnitine supplementation improves hematological pattern in patients affected
by HCV treated with Peg interferon-α 2b plus ribavirin. World J. Gastroenterol. WJG 2011, 17, 4414–4420.
[CrossRef] [PubMed]
122. Mescka, C.P.; Guerreiro, G.; Hammerschmidt, T.; Faverzani, J.; de Moura Coelho, D.; Mandredini, V.;
Wayhs, C.A.Y.; Wajner, M.; Dutra-Filho, C.S.; Vargas, C.R. l-carnitine supplementation decreases DNA
damage in treated MSUD patients. Mutat. Res. 2015, 775, 43–47. [CrossRef] [PubMed]
123. Giammarioli, S.; Boniglia, C.; Carratu, B.; Ciarrocchi, M.; Chiarotti, F.; Mosca, M.; Sanzini, E. Use of food
supplements and determinants of usage in a sample Italian adult population. Public Health Nutr. 2013, 16,
1768–1781. [CrossRef] [PubMed]
124. Santini, A.; Novellino, E. Nutraceuticals: Beyond the diet before the drugs. Curr. Bioact. Compounds 2014, 10,
1–12. [CrossRef]
125. Santini, A.; Novellino, E. To nutraceuticals and back: Rethinking a concept. Foods 2017, 6, 74. [CrossRef]
126. Abenavoli, L.; Izzo, A.A.; Milic´, N.; Cicala, C.; Santini, A.; Capasso, R. Milk thistle (Silybum marianum):
A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother. Res.
2018, 32, 2202–2213. [CrossRef]
Molecules 2020, 25, 2127 18 of 19
127. Santini, A.; Tenore, G.C.; Novellino, E. Nutraceuticals: A paradigm of proactive medicine. Eur. J. Pharm. Sci.
2017, 96, 53–61. [CrossRef]
128. Daliu, P.; Santini, A.; Novellino, E. A decade of nutraceutical patents: Where are we now in 2018? Expert Opin.
Ther. Pat. 2018, 28, 875–882. [CrossRef]
129. Durazzo, A.; Lucarini, M.; Santini, A. Nutraceuticals in Human Health. Foods 2020, 9, 370. [CrossRef]
130. Durazzo, A. Extractable and Non-extractable polyphenols: An overview. In Non-Extractable Polyphenols and
Carotenoids: Importance in Human Nutrition and Health; Saura-Calixto, F., Pérez-Jiménez, J., Eds.; Royal Society
of Chemistry: London, UK, 2018; pp. 1–37. [CrossRef]
131. Durazzo, A.; Lucarini, M. A current shot and re-thinking of antioxidant research strategy. Braz. J. Anal. Chem.
2018, 5, 9–11. [CrossRef]
132. Santini, A.; Novellino, E. Nutraceuticals-shedding light on the grey area between pharmaceuticals and food.
Expert Rev. Clin. Pharmacol. 2018, 11, 545–547. [CrossRef] [PubMed]
133. Santini, A.; Cammarata, S.M.; Capone, G.; Ianaro, A.; Tenore, G.C.; Pani, L.; Novellino, E. Nutraceuticals:
Opening the debate for a regulatory framework. Br. J. Clin. Pharmacol. 2018, 84, 659–672. [CrossRef]
134. Daliu, P.; Santini, A.; Novellino, E. From pharmaceuticals to nutraceuticals: Bridging disease prevention and
management. Expert. Rev. Clin. Pharm. 2019, 12, 1–7. [CrossRef] [PubMed]
135. Durazzo, A.; Lucarini, M. Extractable and non-extractable antioxidants. Molecules 2019, 24, 1933. [CrossRef]
[PubMed]
136. Durazzo, A.; Lucarini, M.; Souto, E.B.; Cicala, C.; Caiazzo, E.; Izzo, A.A.; Novellino, E.; Santini, A. Polyphenols:
A concise overview on the chemistry, occurrence, and human health. Phytother. Res. 2019, 33, 2221–2243.
[CrossRef] [PubMed]
137. Virji, A. Potential benefits of l-carnitine as dietary supplement. Am. Fam. Phys. 2017, 96, 11.
138. de Andrés, F.; Castañeda, G.; Ríos, Á. Achiral liquid chromatography with circular dichroism detection
for the determination of carnitine enantiomers in dietary supplements and pharmaceutical formulations.
J. Pharm. Biomed. Anal. 2010, 51, 478–483. [CrossRef]
139. Sánchez-Hernández, L.; Castro-Puyana, M.; García-Ruiz, C.; Crego, A.L.; Marina, M.L. Determination of L-
and D-carnitine in dietary food supplements using capillary electrophoresis–tandem mass spectrometry.
Food Chem. 2010, 120, 921–928. [CrossRef]
140. Isaguirre, A.C.; Acosta, G.; Cerutti, S.; Fernandez, L.P. New flow injection method for quality control of dietary
supplements containing l-carnitine using extraction mediated by sodium taurodeoxycholate coacervate
coupled to molecular fluorescence. Microchem. J. 2016, 129, 268–273. [CrossRef]
141. Voitiuk, O.; Yegorova, A.; Scrypynets, Y.V.; Kashutskyy, S.; Kluchnik, O.; Umetskaya, I. HPLC-determination
of active components in dietary supplement « l-carnitine smart». Farmatsevtychnyi zhurnal 2019, 86–96.
[CrossRef]
142. Ellingson, D.J.; Shippar, J.J.; Gilmore, J.M. Determination of free and total choline and carnitine in infant
formula and adult/pediatric nutritional formula by liquid chromatography/tandem mass spectrometry
(LC/MS/MS): Single-laboratory validation, first action 2015.10. J. AOAC Int. 2016, 99, 204–209. [CrossRef]
[PubMed]
143. Johnson, D.W. An acid hydrolysis method for quantification of plasma free and total carnitine by flow
injection tandem mass spectrometry. Clin. Biochem. 2010, 43, 1362–1367. [CrossRef] [PubMed]
144. Dwyer, J.T.; Saldanha, L.G.; Bailen, R.A.; Bailey, R.L.; Costello, R.B.; Betz, J.M.; Chang, F.F.; Goshorn, J.;
Andrews, K.W.; Pehrsson, P.R. A free new dietary supplement label database for registered dietitian
nutritionists. J. Acad. Nutr. Dietet. 2014, 114, 1517. [CrossRef] [PubMed]
145. DSLD-Dietary Supplement Label Database. Available online: https://dsld.nlm.nih.gov/dsld/ (accessed on
2 April 2020).
146. Brown, A.C. An overview of herb and dietary supplement efficacy, safety and government regulations in
the United States with suggested improvements. Part 1 of 5 series. Food. Chem. Toxicol. 2017, 107, 449–471.
[CrossRef]
147. Potischman, N.; Salazar, S.; Susser, J.; Saldanha, L.; Dwyer, J.; Kuzak, A.; Betz, J.; Bailen, R. Testing usability
of the Dietary Supplement Label Database (DSLD): A resource for consumers, professionals, and researchers.
J. Nutr. Edu. Behav. 2017, 49, S99. [CrossRef]
Molecules 2020, 25, 2127 19 of 19
148. Dwyer, J.T.; Bailen, R.A.; Saldanha, L.G.; Gahche, J.J.; Costello, R.B.; Betz, J.M.; Davis, C.D.; Bailey, R.L.;
Potischman, N.; Ershow, A.G. The dietary supplement label database: Recent developments and applications.
J. Nutr. 2018, 148, 1428S–1435S. [CrossRef]
149. Durazzo, A.; Camilli, E.; D’Addezio, L.; Piccinelli, R.; Mantur-Vierendeel, A.; Marletta, L.; Finglas, P.;
Turrini, A.; Sette, S. Development of Dietary Supplement Label Database in Italy: Focus of FoodEx2 Coding.
Nutrition 2020, 12, 89. [CrossRef]
150. Durazzo, A.; D’Addezio, L.; Camilli, E.; Piccinelli, R.; Turrini, A.; Marletta, L.; Marconi, S.; Lucarini, M.;
Lisciani, S.; Gabrielli, P. From plant compounds to botanicals and back: A current snapshot. Molecules 2018,
23, 1844. [CrossRef]
151. European Food Safety Authority. Classification and description system FoodEx2 (revision 2). EFSA J. 2015,
12, EN-804.
152. Goin-Kochel, R.P.; Scaglia, F.; Schaaf, C.P.; Berry, L.N.; Dang, D.; Nowel, K.P.; Laakman, A.L.; Dowell, L.R.;
Minard, C.G.; Loh, A. Side effects and behavioral outcomes following high-dose carnitine supplementation
among young males with autism spectrum disorder: A pilot study. Glob. Pediatr. Health 2019, 6,
2333794X19830696. [CrossRef]
153. Malaguarnera, M.; Cauli, O. Effects of l-carnitine in Patients with Autism Spectrum Disorders: Review of
Clinical Studies. Molecules 2019, 24, 4262. [CrossRef] [PubMed]
154. Ussher, J.R.; Lopaschuk, G.D.; Arduini, A. Gut microbiota metabolism of l-carnitine and cardiovascular risk.
Atherosclerosis 2013, 231, 456–461. [CrossRef] [PubMed]
155. Vallance, H.D.; Koochin, A.; Branov, J.; Rosen-Heath, A.; Bosdet, T.; Wang, Z.; Hazen, S.L.; Horvath, G.
Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders
treated with oral l-carnitine. Mol. Genet. Metabol. Rep. 2018, 15, 130–133. [CrossRef] [PubMed]
156. Tang, W.W.; Wang, Z.; Levison, B.S.; Koeth, R.A.; Britt, E.B.; Fu, X.; Wu, Y.; Hazen, S.L. Intestinal microbial
metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 2013, 368, 1575–1584. [CrossRef]
[PubMed]
157. Janeiro, M.H.; Ramírez, M.J.; Milagro, F.I.; Martínez, J.A.; Solas, M. Implication of trimethylamine N-Oxide
(TMAO) in disease: Potential biomarker or new therapeutic target. Nutrition 2018, 10, 1398. [CrossRef]
[PubMed]
158. Zhu, Y.; Jameson, E.; Crosatti, M.; Schäfer, H.; Rajakumar, K.; Bugg, T.D.; Chen, Y. Carnitine metabolism to
trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. USA
2014, 111, 4268–4273. [CrossRef] [PubMed]
159. Asadi, M.; Rahimlou, M.; Shishehbor, F.; Mansoori, A. The effect of l-carnitine supplementation on lipid profile
and glycaemic control in adults with cardiovascular risk factors: A systematic review and meta-analysis of
randomized controlled clinical trials. Clin. Nutr. 2020, 39, 110–122. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
